TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Atorvastatin on Myonecrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be aged 18 or over.~* Patients must provide written informed consent.~* Patients are presenting with unstable angina (defined as new onset chest pain, accelerating chest pain, chest pain at rest and ST-segment depression on the electrocardiogram \[EKG\])~* Patients undergoing successful coronary stent implantation of the (presumed) culprit lesion (defined as \< 50% residual stenosis).~Exclusion Criteria:~* Any patient who is unable to give written informed consent.~* Any condition which, in the investigator's opinion, would interfere with optimal participation in the study or produce a significant risk to the patient.~* Patients presenting with an ST-elevation myocardial infarction (MI).~* Patients with elevated troponin, CK, or CK-MB (above the upper limit of normal).~* Patients already on high-dose statin therapy (defined as any statin equivalent to atorvastatin ≥ 40 mg).~* Patients who took any statin agent within 24 hours of presentation to the cardiac catheterization laboratory.~* Patients with active hepatic disease or myositis, in whom statin therapy is contraindicated.~* Patients with hypersensitivity to atorvastatin.~* Patients with procedural complications, including unsuccessful percutaneous transluminal coronary angioplasty (PTCA)/stenting, major side-branch occlusion, flow-limiting dissections at the completion of the procedure, emergent coronary artery bypass surgery, peri-procedural thrombus formation with distal embolization, stent thrombosis within the first 24 hours, repeat emergent PCI within 24 hours, and death within 24 hours.~* Cardiogenic shock.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- atorvastatin 80 mg (Type: ACTIVE_COMPARATOR): 80 mg atorvastatin on average of 2-4 hours pre angio/PCI for ACS
- placebo oral tablet (Type: PLACEBO_COMPARATOR): placebo on average of 2-4 hours pre angio/PCI for ACS
- Screening (Type: NO_INTERVENTION): Patients signed consent if willing to participate. Patients will continue onto randomization if appropriate per inc/exc (i.e. stent placement) otherwise screen fail

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have histologically or cytologically confirmed carcinoma of the head and neck region. Primary tumor sites include: lip and oral cavity, major salivary glands, pharynx (oropharynx, nasopharynx, hypopharynx), or larynx (supraglottis, glottis, subglottis), nasal cavity and paranasal sinuses, and thyroid~* Patients must have metastatic or locally recurrent squamous cell carcinoma of the head and neck. Patients with locoregional disease must be considered incurable by means of locoregional therapy.~* All sites of disease must be assessed and designated as measurable or non-measurable disease as documented by CT, MRI, X-ray physical exam or nuclear exam. All measurable and non-measurable disease must be assessed within 28 days prior to registration.~* Patients may have prior chemotherapy for recurrent/metastatic disease. However, all chemotherapy must be completed at least 21 days prior to scheduled start of Abraxane.~* Patients must have adequate bone marrow reserve as documented by absolute neutrophil count (ANC) \> 1,500 μl and platelets \> 100,000/ μl obtained within 14 days prior to registration.~* Patients must have adequate hepatic as documented by serum bilirubin \< 1.5 x the institutional upper limit of normal. These tests must be obtained within 14 days prior to registration.~* All patients must be 18 years of age or older~* Patients must have a Zubrod performance of 0-3~Exclusion Criteria:~* Patients must not have prior therapy with Abraxane~* Patients with any evidence of active or uncontrolled infection, recent myocardial infection, unstable angina, or life-threatening arrhythmia are not eligible.~* Patients with baseline grade 3 peripheral neuropathy are not eligible.~* Patients with known brain metastasis are not eligible. However, brain-imaging studies are not required for eligibility if the patient has no neurological signs or symptoms. If brain-imaging studies are performed, they must be negative for disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abraxane plus Cetuximab (Type: EXPERIMENTAL): Drug: Abraxane-260 mg/m2 IV over 30 minutes every 3 weeks. Drug: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adrenalectomy Versus Follow-up in Patients With Subclinical Cushings Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adrenal tumour with biochemical mild hypercortisolism defined as pathological dexamethasone suppression test (cortisol \> 50 nmol/L at 8.00 am after 1 mg dexamethasone at 10 pm, plus one of the following criteria~  * Low or suppressed adrenocorticotropic hormone (ACTH)~ * Low or suppressed dehydroepiandrosterone (DHEA)~ * No or pathological circadian rhythm of cortisol~Exclusion Criteria:~* Increased levels of 24 hours urinary excretion of cortisol~* Pregnancy or lactation~* Inability to understand information or to comply with scheduled follow-up~* Mild hypercortisolism with bilateral adrenal tumours, without a gradient (lateralization on venous sampling)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Follow-up (Type: NO_INTERVENTION): Patients who are diagnosed with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), who are followed only.
- Surgery (Type: EXPERIMENTAL): Patients diagnosed with adrenal tumour and with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), operated with adrenalectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early TIPS for Ascites Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~\> Patient has cirrhosis of the liver with portal hypertension~\> Patient has difficult to treat ascites~\> Patient is 18 years or older and \<70 years old at randomization~\> Patient is willing and able to comply with all study protocol requirements, including specified follow-up and testing.~\> Patient, or legal authorized representative, is willing to provide written informed consent prior to enrollment in the study.~Exclusion Criteria:~\> Patient has more than 6 large volume paracenteses within 90 days prior to randomization~\> Patient is contraindicated for TIPS placement~\> Patient has had previous TIPS placement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- TIPS (Type: EXPERIMENTAL): TIPS with GORE® VIATORR® TIPS Endoprosthesis
- LVP (Type: ACTIVE_COMPARATOR): Large Volume Paracentesis~\*A subject may be crossed-over from large volume paracentesis to TIPS with GORE® VIATORR® TIPS Endoprosthesis if the subject has completed their six month study visit and has met the criteria for cross-over (LVP failure).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study in Leucocytes From Patients With Type 1 and Type 2 Diabetes Genetic Markers of Inflammation and Oxidative Stress (TÉLOMÈRES/ CANDIDATE GENES) According to the Type A or Type B Behavior Profile

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have provided written informed consent~* Patients with type 1 or type 2 diabetes~* Patient admitted for a consultation, as out or in-patients to the Endocrinology-Diabetology-Metabolic diseases department of Dijon CHU~* Patient \> 18 years~* Patient with either a characteristic Type A behaviour profile (Bortner \> 210), or a characteristic Type B behaviour profile (Bortner\<154)~Exclusion Criteria:~* Persons not covered by national health insurance~* Adults under guardianship or wards of court or not intellectually independent~* Patients without diabetes~* Patients with a mixed A/B behaviour profile (154\< Bortner score \<210)~* Pregnant or breast-feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Type A behaviour profile (Type: OTHER): None
- Type B behaviour profile (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Randomized-controlled Trial of a Combined vs. Conventional Percutaneous Intervention for Near-Infrared Spectroscopy Defined High-Risk Native Coronary Artery Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years.~2. Willing and able to provide informed consent and able to comply with study procedures and follow-up.~3. Undergoing a clinically indicated left heart coronary catheterization~4. Need PCI of a high-risk native coronary artery lesion. High-risk lesions will be defined as lesions with ≥2 contiguous yellow blocks on block chemogram.~Exclusion Criteria:~1. Coexisting conditions that limit life expectancy to less than 30-days or that could affect the patient's compliance with the protocol.~2. Positive pregnancy test or breast-feeding.~3. High risk for bleeding.~4. Subject is currently, or within the 30 preceding days, participating in a device or pharmaceutical treatment protocol.~5. Clinical presentation with ST-segment elevation MI.~6. Persistent (\>10 minutes) hypotension (systolic blood pressure \<90 mmHg)~7. Need for revascularization of multiple lesions during the index PCI.~8. Unprotected left main (\>50%) or equivalent left main disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combined Intervention (Type: ACTIVE_COMPARATOR): Combined intervention: pre-PCI intracoronary vasodilator and glycoprotein IIb/IIIa inhibitor administration, use of an EPD if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
- Conventional PCI (Type: ACTIVE_COMPARATOR): Conventional PCI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants are required to remain in the clinical facility from Day -1 (Part 1) or Day -2 (Part 2) until clinic discharge.~* A negative test for COVID-19, which will be performed in the manner mandated by the clinical site where this study is being conducted, at screening and admission.~* All female participants, Women of Childbearing Potential (WOCBP) and women not of childbearing potential, must have a negative highly sensitive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG)) at screening and on Day -1 (or Day -2 for Part 2).~Exclusion Criteria:~* Participant was exposed to an investigational drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever is longer).~* Vaccination or plans for vaccination with non-live vaccines within 30 days before Day -1 (for Day -2 for Part 2) until the follow-up phone call.~* Donation of blood or blood transfusion within 8 weeks of first study intervention administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BMS-986421 Under Fasted Conditions (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Wii Fit (TM) to Increase Compliance With Home Exercises in Treating Patellofemoral Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female between ages of 11 and 17 years of age~* A diagnosis of patellofemoral syndrome with one or more of the following symptoms: anterior knee pain, positive theater sign, stairs provoking knee pain.~* No physiotherapy or regular, structured home exercise program is being followed~* Parental/guardian consent to participate~* Patient assent to participate~Exclusion Criteria:~* Patients participating in physiotherapy at the time of initial assessment or have had physiotherapy in the last 6 months for patellofemoral syndrome~* Patients performing regular home exercise program prescribed by physician, physiotherapist, or other allied health professional for patellofemoral syndrome at time of initial assessment~* Patients who have additional knee pathology (e.g. acute patellar dislocation; acute internal knee derangement (i.e. meniscal, ligament injury); osteochondritis dissecans; severe apophysitis or tendinitis) that could interfere with rehabilitation exercises due to pain or instability from these conditions~* Individuals with history of knee surgery~* Individuals that have a Wii Fit TM video game at home~* Individuals for whom consent and assent is not obtained

- Gender: FEMALE
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Wii Fit (TM) Interactive Video Game (Type: EXPERIMENTAL): Wii Fit (TM) Interactive Video Game
- Traditional Home Exercise Program (Type: ACTIVE_COMPARATOR): Traditional Home Exercise Program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcutaneous Oximetry, Transcutaneous Carbon Dioxide and Supplemental Oxygen Therapy in Lower Limb Amputations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Requires a lower limb amputation between the ankle and knee due to vascular complications~3. Provides written informed consent~Exclusion Criteria:~1. Requires a lower limb amputation for non-vascular reasons, including trauma and cancer~2. Requires primary amputation below the level of the ankle or above the knee

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- leg amputation (Type: None): Patients undergoing below-knee and above ankle amputation for vascular reasons will receive transcutaneous oximetry and transcutaneous carbon dioxide measurement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Novel Use of an Enhanced Fluoroscopic Imaging Device to Reduce Radiation Exposure and Operative Time During Intramedullary Nailing of Hip Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* closed hip fracture requiring intramedullary nailing~Exclusion Criteria:~* age \<18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Digital Image Enhancement (DIE) Group (Type: EXPERIMENTAL): A novel digital image enhancement technology will be used intraoperatively
- Control Group (Type: NO_INTERVENTION): Standard intraoperative imaging will be used intraoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose Individualization of Pemetrexed - IMPROVE-II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥18 years old~2. Eligible for treatment with pemetrexed-based chemotherapy~3. Creatinine clearance \>45ml/min~4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2~5. Subject is able and willing to sign the Informed Consent Form~Exclusion Criteria:~1. Conditions that affect haemostasis in a way that blood drawing is complicated (to be assessed by physician)~2. Contraindications for treatment with pemetrexed in line with the summary of product characteristics (SmPC) (except for creatinine clearance \<45 ml/min in IMPROVE-I)~   1. Hypersensitivity to the active substance or to any of the excipients~  2. Pregnancy or lactation~  3. Concomitant yellow fever vaccine~3. The presence of clinically relevant pharmacokinetic interactions, according to the current SmPC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (BSA-based dosing) (Type: ACTIVE_COMPARATOR): Dosing of pemetrexed is based on BSA according drug label
- Arm B (renal function based dosing) (Type: EXPERIMENTAL): Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SI Joint Fusion and Decortication Using the SImmetry System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be indicated for the SImmetry device according to the approved SImmetry labeling~* Subject has two (2) positive (experiences pain) Provocative Tests for SIJ pain; for example, Compression, Thigh Thrust, FABER, Distraction or Gaenslen's~* Subject has documentation of failed, non-operative management of SIJ pain for ≥ 6 months prior to surgery; for example, use of medications, braces, SI belts, orthotics, physical therapy or manual manipulation~* The subject has two (2) diagnostic SIJ injection at least one (1) resulting in a ≥50% decrease in pain in the joint(s) from the anesthetic portion of the injection~* The subject has VAS back pain score of ≥ 50 mm~* The subject is at least 18 years of age and skeletally mature~* The subject agrees and is able to comply with study requirements~Exclusion Criteria:~* Subjects contraindicated per the cleared labeling will be excluded from participation in the study~* The subject has pelvic soft tissue or bony tumors~* The subject has had any trauma causing fracture of the sacrum or iliac bones or has had spinal trauma leading to a neurological deficit~* The subject has a history of a central nervous system (CNS) disorder(s)~* The subject is indicated for or awaiting other spine surgery~* The subject is pregnant or is planning on becoming pregnant in the next two years~* The subject has uncontrolled insulin dependent diabetes mellitus (Type 1 Diabetes)~* The subject has chemical dependency abuse problems as evidenced by a history of abusing drugs which is documented in their past medical history or is elicited from an interview~* The subject is receiving or seeking worker's compensation, disability remuneration, and/or involved in litigation related to low back or SIJ pain~* The subject has a history of significant emotional or psychosocial disturbance (untreated or uncontrolled anxiety attacks, obsessive/compulsive disorders, depression or schizophrenia) as documented in their past medical history or elicited by an interview

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues